Aligos Therapeutics (ALGS) Operating Expenses (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Operating Expenses came in at $29.8 million in Q1 2026, up 52.19% YoY from $19.6 million in Q1 2025, and up 35.37% on a QoQ basis from $22.0 million in Q4 2025.
Aligos Therapeutics (ALGS) Operating Expenses (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Operating Expenses data on file, last reported at $29.8 million in Q1 2026.
- Quarterly Operating Expenses rose 52.19% year-over-year to $29.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100.4 million (up 12.0% YoY) and the FY2025 annual result came in at $90.2 million, down 3.15% from the prior year.
- Operating Expenses improved to $29.8 million in Q1 2026, from $22.0 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $38.1 million in Q1 2022 to a low of $19.5 million in Q2 2025.
- A 5-year average of $25.2 million and a median of $24.1 million in 2022 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses plunged 33.38% — and 2026, when it jumped 52.19%.
- Tracing ALGS's Operating Expenses over 5 years: stood at $26.2 million in 2022, then gained by 9.38% to $28.7 million in 2023, then declined by 26.1% to $21.2 million in 2024, then rose by 3.73% to $22.0 million in 2025, then surged by 35.37% to $29.8 million in 2026.
- The last three Operating Expenses figures came in at $29.8 million (Q1 2026), $22.0 million (Q4 2025), and $29.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Aligos Therapeutics | 67.38 Mn | 36.94 Mn | - | 29.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.67 Mn |
| Mar 31, 2026 | 29.76 Mn |
| Dec 31, 2025 | 21.98 Mn |
| Sep 30, 2025 | 29.10 Mn |
| Jun 30, 2025 | 19.53 Mn |
| Mar 31, 2025 | 19.55 Mn |
| Dec 31, 2024 | 21.19 Mn |
| Sep 30, 2024 | 21.40 Mn |
| Jun 30, 2024 | 27.48 Mn |
| Mar 31, 2024 | 23.03 Mn |
| Dec 31, 2023 | 28.68 Mn |
| Sep 30, 2023 | 22.31 Mn |
| Jun 30, 2023 | 26.03 Mn |
| Mar 31, 2023 | 26.64 Mn |
| Dec 31, 2022 | 26.22 Mn |
| Sep 30, 2022 | 23.05 Mn |
| Jun 30, 2022 | 24.09 Mn |
| Mar 31, 2022 | 38.13 Mn |
| Dec 31, 2021 | 38.32 Mn |
| Sep 30, 2021 | 34.61 Mn |